Agios Pharm Ownership
| AGIO Stock | USD 34.44 0.75 2.13% |
Shares in Circulation | First Issued 2012-03-31 | Previous Quarter 58.4 M | Current Value 57.9 M | Avarage Shares Outstanding 47.9 M | Quarterly Volatility 14.1 M |
Agios |
Agios Stock Ownership Analysis
About 99.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.32. Some equities with similar Price to Book (P/B) outperform the market in the long run. Agios Pharm recorded earning per share (EPS) of 11.64. The entity had not issued any dividends in recent years. Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Agios Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 0 people. For more info on Agios Pharm please contact Brian MBA at 617 649 8600 or go to https://www.agios.com.Besides selling stocks to institutional investors, Agios Pharm also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Agios Pharm's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Agios Pharm's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Agios Pharm Quarterly Liabilities And Stockholders Equity |
|
Agios Pharm Insider Trades History
Only 1.5% of Agios Pharm are currently held by insiders. Unlike Agios Pharm's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Agios Pharm's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Agios Pharm's insider trades
Agios Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Agios Pharm is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Agios Pharm backward and forwards among themselves. Agios Pharm's institutional investor refers to the entity that pools money to purchase Agios Pharm's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 1.3 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.3 M | Bvf Inc | 2024-12-31 | 1.1 M | Polar Capital Holdings Plc | 2024-09-30 | 1 M | Fisher Asset Management, Llc | 2024-12-31 | 960.7 K | Bnp Paribas Investment Partners Sa | 2024-12-31 | 942.2 K | Deutsche Bank Ag | 2024-12-31 | 935.3 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 917.4 K | Gw&k Investment Management, Llc | 2024-12-31 | 683.5 K | Farallon Capital Management, L.l.c. | 2024-12-31 | 5.7 M | Vanguard Group Inc | 2024-12-31 | 5.6 M |
Agios Pharm Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Agios Pharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on Agios Pharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Agios Pharm insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Agios Pharm's latest congressional trading
Congressional trading in companies like Agios Pharm, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Agios Pharm by those in governmental positions are based on the same information available to the general public.
| 2025-02-12 | Representative Gil Cisneros | Acquired Under $15K | Verify |
Agios Pharm Outstanding Bonds
Agios Pharm issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Agios Pharm uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Agios bonds can be classified according to their maturity, which is the date when Agios Pharm has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ADVGRO 8625 30 SEP 27 Corp BondUS00840KAA79 | View | |
| US00842XAA72 Corp BondUS00842XAA72 | View | |
| US00846UAL52 Corp BondUS00846UAL52 | View | |
| AGILENT TECHNOLOGIES INC Corp BondUS00846UAK79 | View | |
| AGILENT TECHNOLOGIES INC Corp BondUS00846UAN19 | View | |
| Agilent Technologies 21 Corp BondUS00846UAM36 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Agios Pharm Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 13th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pair Trading with Agios Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.Moving against Agios Stock
| 0.64 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.6 | GANX | Gain Therapeutics | PairCorr |
| 0.6 | PHGE | Biomx Inc | PairCorr |
| 0.59 | XFOR | X4 Pharmaceuticals | PairCorr |
| 0.52 | OPT | Opthea | PairCorr |
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.64 | Revenue Per Share | Quarterly Revenue Growth 0.511 | Return On Assets | Return On Equity |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.